95%Confidence
0Views
FDASource
2026-05-26Date
Summary
A second Ajanta Pharma duloxetine product with nitrosamine impurity reinforces systemic quality issues, increasing the risk of broader regulatory scrutiny and market withdrawal. This may accelerate FDA enforcement actions against the company.
Actionable: Sell holdings in Ajanta Pharma and avoid its duloxetine products; consider shorting the stock.
AI Confidence: 95%
Data Points
firmAjanta Pharma Ltd.
classificationClass II
statusOngoing
distributionNationwide within U.S
productDuloxetine Delayed-Release Capsules, 20 mg, Rx Only, 60 capsules, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807, Made in India, NDC 27241
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now